Navigation Links
Profectus Biosciences to Present at Key Investor Conference in January 2010
Date:1/8/2010

Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates to treat chronic viral infections, announced today that the company will present at the upcoming Biotech Showcase investor conference and will be attending the J.P. Morgan Healthcare Conference in San Francisco.

Baltimore, MD (Vocus) January 6, 2010 -- Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates to treat chronic viral infections, announced today that the company will present at the upcoming Biotech Showcase investor conference and will be attending the J.P. Morgan Healthcare Conference in San Francisco. These conferences will provide strategic investment and partnering opportunities for Profectus, whose novel ProfectusVAX™ prime/boost vaccines and NF-kB small molecule programs continue to progress on the cutting edge of research and development.

Dr. John Eldridge, Chief Scientific Officer of Profectus BioSciences, commented, “It is an exciting time for vaccine development. Recent clinical data have validated both prime/boost vaccination and the use of therapeutic vaccines to treat chronic viral infections. The Profectus vaccine program has made excellent progress over the past year and will be initiating three proof-of-concept clinical trials in collaboration with the National Institutes of Health (NIH) in 2010. In addition, we have generated very positive preclinical results in our NF-kB small molecule program. We look forward to sharing these successful corporate and R&D results at these conferences, and reaching our clinical milestones in 2010.”

2010 Biotech Showcase, January 12-13, 2010, San Francisco, CA
Oral Presentation:
Who: Dr. John Eldridge
Title: Chief Scientific Officer
When: Wednesday, January 13, 9:40 AM
Where: Heritage Room, 10th Floor, Marines’ Memorial Club & Hotel
Website: www.biotechshowcase.com

About Profectus BioSciences Inc.
Profectus Biosciences is an innovative R&D clinical-stage vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. ProfectusVAX™, the Profectus proprietary vaccine approach combines its plasmid (p) DNA and rVSV (recombinant Vesicular Stomatitis Virus) vector platforms in a unique prime-boost strategy to enhance immune responses to viruses that cause chronic disease. Profectus has a pipeline of proprietary vaccine products to address diseases caused by Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), and Herpes Simplex Virus (HSV) as well as for Malaria. The first of three proof-of-concept clinical trials with the prime/boost HIV vaccine candidate is planned for H1 of 2010, followed by a therapeutic HCV vaccine.

The Profectus portfolio has secured over $100M in non-dilutive funding of its programs from multiple sources including the National Institutes of Health (NIH) and $19M in private equity financing, including Cross Atlantic Capital Partners (XACP). Profectus deploys these financial resources in support of its proprietary prime-boost vaccines for multiple indications. In addition, the Company is funding its early research small molecule program for potential partners. For more information, please visit: http://www.profectusbiosciences.com.

Contact:
Lisa Rivero
LaVoie Group
978-745-4200 x106
http://www.lavoiegroup.com

###

Read the full story at http://www.prweb.com/releases/biopharmaceutical/profectus_conference/prweb3413824.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
2. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
3. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
4. David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc.
5. YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract
6. Nu-Tek BioSciences, LLC. Launches Animal-Free, Non-GM Soy Peptone
7. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
8. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
9. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
10. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
11. Cell Biosciences Acquires Protein Forest
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Profectus Biosciences to Present at Key Investor Conference in January 2010
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
Breaking Biology Technology:
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:3/30/2017)...  On April 6-7, 2017, Sequencing.com will host the ... hackathon at Microsoft,s headquarters in Redmond, Washington ... developing health and wellness apps that provide a unique, ... is the first hackathon for personal genomics and ... in the genomics, tech and health industries are sending ...
Breaking Biology News(10 mins):